Northern Trust Corp increased its stake in OncoCyte Co. (NYSEAMERICAN:OCX) by 1.9% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 678,620 shares of the biotechnology company’s stock after acquiring an additional 12,751 shares during the period. Northern Trust Corp owned approximately 1.01% of OncoCyte worth $1,622,000 as of its most recent SEC filing.
A number of other hedge funds also recently modified their holdings of OCX. BlackRock Inc. boosted its holdings in OncoCyte by 26.7% in the 3rd quarter. BlackRock Inc. now owns 3,293,383 shares of the biotechnology company’s stock worth $4,577,000 after acquiring an additional 694,768 shares during the period. State Street Corp boosted its position in OncoCyte by 9.6% in the 3rd quarter. State Street Corp now owns 684,637 shares of the biotechnology company’s stock valued at $952,000 after buying an additional 59,985 shares during the last quarter. JPMorgan Chase & Co. grew its stake in shares of OncoCyte by 31.0% during the third quarter. JPMorgan Chase & Co. now owns 48,279 shares of the biotechnology company’s stock valued at $69,000 after acquiring an additional 11,414 shares in the last quarter. California State Teachers Retirement System boosted its holdings in OncoCyte by 45.9% in the third quarter. California State Teachers Retirement System now owns 95,193 shares of the biotechnology company’s stock valued at $132,000 after purchasing an additional 29,966 shares during the last quarter. Finally, Caliber Wealth Management LLC purchased a new stake in OncoCyte during the 4th quarter worth approximately $82,000. 46.53% of the stock is owned by hedge funds and other institutional investors.
In other OncoCyte news, CEO Ronald Asbury Andrews bought 11,000 shares of the stock in a transaction on Friday, March 19th. The shares were bought at an average price of $4.79 per share, with a total value of $52,690.00. Following the purchase, the chief executive officer now directly owns 113,698 shares in the company, valued at approximately $544,613.42. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. 5.64% of the stock is currently owned by corporate insiders.
OncoCyte (NYSEAMERICAN:OCX) last released its quarterly earnings data on Monday, March 15th. The biotechnology company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.02. As a group, sell-side analysts expect that OncoCyte Co. will post -0.46 earnings per share for the current year.
A number of research analysts have commented on the stock. Benchmark increased their price objective on shares of OncoCyte from $6.00 to $11.00 and gave the company a “buy” rating in a research note on Wednesday, March 17th. Zacks Investment Research cut OncoCyte from a “buy” rating to a “hold” rating in a research note on Saturday, February 20th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $8.00 price target on shares of OncoCyte in a report on Tuesday, March 23rd. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $6.50.
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay.
Recommended Story: How is Preferred Stock Different from Common Stock?
Receive News & Ratings for OncoCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoCyte and related companies with MarketBeat.com's FREE daily email newsletter.